Success Metrics

Clinical Success Rate
50.0%

Based on 2 completed trials

Completion Rate
50%(2/4)
Active Trials
0(0%)
Results Posted
100%(2 trials)
Terminated
2(50%)

Phase Distribution

Ph phase_2
1
25%
Ph not_applicable
2
50%
Ph phase_1
1
25%

Phase Distribution

1

Early Stage

1

Mid Stage

0

Late Stage

Phase Distribution4 total trials
Phase 1Safety & dosage
1(25.0%)
Phase 2Efficacy & side effects
1(25.0%)
N/ANon-phased studies
2(50.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

50.0%

2 of 4 finished

Non-Completion Rate

50.0%

2 ended early

Currently Active

0

trials recruiting

Total Trials

4

all time

Status Distribution
Completed(2)
Terminated(2)

Detailed Status

Completed2
Terminated2

Development Timeline

Analytics

Development Status

Total Trials
4
Active
0
Success Rate
50.0%
Most Advanced
Phase 2

Trials by Phase

Phase 11 (25.0%)
Phase 21 (25.0%)
N/A2 (50.0%)

Trials by Status

completed250%
terminated250%

Recent Activity

0 active trials
Showing 4 of 4
completedphase_1

Effect of Gemcabene on the Pharmacokinetics of Simvastatin in Healthy Volunteers

NCT02587390
terminatedphase_2

Simvastatin For Intracerebral Hemorrhage Study

NCT00718328
terminatednot_applicable

Use of Simvastatin for the Prevention of Vasospasm in Aneurysmal Subarachnoid Hemorrhage

NCT00487461
completednot_applicable

Effects on NF-κB Activity: High Dose Simvastatin Versus Combination Therapy With Ezetimibe

NCT01424891

Clinical Trials (4)

Showing 4 of 4 trials
NCT02587390Phase 1

Effect of Gemcabene on the Pharmacokinetics of Simvastatin in Healthy Volunteers

Completed
NCT00718328Phase 2

Simvastatin For Intracerebral Hemorrhage Study

Terminated
NCT00487461Not Applicable

Use of Simvastatin for the Prevention of Vasospasm in Aneurysmal Subarachnoid Hemorrhage

Terminated
NCT01424891Not Applicable

Effects on NF-κB Activity: High Dose Simvastatin Versus Combination Therapy With Ezetimibe

Completed

All 4 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
4